These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19294736)

  • 21. E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: correlation with morphology and CDH1 somatic alterations.
    Grabenstetter A; Mohanty AS; Rana S; Zehir A; Brannon AR; D'Alfonso TM; DeLair DF; Tan LK; Ross DS
    Hum Pathol; 2020 Aug; 102():44-53. PubMed ID: 32599083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast.
    Green AR; Krivinskas S; Young P; Rakha EA; Paish EC; Powe DG; Ellis IO
    Breast Cancer Res Treat; 2009 Jan; 113(1):59-66. PubMed ID: 18213475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant expression of E-cadherin in lobular carcinomas of the breast.
    Da Silva L; Parry S; Reid L; Keith P; Waddell N; Kossai M; Clarke C; Lakhani SR; Simpson PT
    Am J Surg Pathol; 2008 May; 32(5):773-83. PubMed ID: 18379416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
    Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
    Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lobular carcinoma, not only a classic.
    Brogi E; Murray MP; Corben AD
    Breast J; 2010; 16 Suppl 1():S10-4. PubMed ID: 21050299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
    Christgen M; Bartels S; van Luttikhuizen JL; Bublitz J; Rieger LU; Christgen H; Stark H; Sander B; Lehmann U; Steinemann D; Derksen PWB; Kreipe H
    Mod Pathol; 2020 Dec; 33(12):2483-2498. PubMed ID: 32572153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium.
    De Schepper M; Koorman T; Richard F; Christgen M; Vincent-Salomon A; Schnitt SJ; van Diest PJ; Zels G; Mertens F; Maetens M; Vanden Bempt I; Harbeck N; Nitz U; Gräser M; Kümmel S; Gluz O; Weynand B; Floris G; Derksen PWB; Desmedt C;
    Mod Pathol; 2024 Jul; 37(7):100497. PubMed ID: 38641322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.
    Dabbs DJ; Schnitt SJ; Geyer FC; Weigelt B; Baehner FL; Decker T; Eusebi V; Fox SB; Ichihara S; Lakhani SR; Palacios J; Rakha E; Richardson AL; Schmitt FC; Tan PH; Tse GM; Vincent-Salomon A; Ellis IO; Badve S; Reis-Filho JS
    Am J Surg Pathol; 2013 Jul; 37(7):e1-11. PubMed ID: 23759937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast.
    Mastracci TL; Shadeo A; Colby SM; Tuck AB; O'Malley FP; Bull SB; Lam WL; Andrulis IL
    Genes Chromosomes Cancer; 2006 Nov; 45(11):1007-17. PubMed ID: 16897748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect.
    Corso G; Figueiredo J; La Vecchia C; Veronesi P; Pravettoni G; Macis D; Karam R; Lo Gullo R; Provenzano E; Toesca A; Mazzocco K; Carneiro F; Seruca R; Melo S; Schmitt F; Roviello F; De Scalzi AM; Intra M; Feroce I; De Camilli E; Villardita MG; Trentin C; De Lorenzi F; Bonanni B; Galimberti V
    J Med Genet; 2018 Jul; 55(7):431-441. PubMed ID: 29929997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9.
    Cao D; Polyak K; Halushka MK; Nassar H; Kouprina N; Iacobuzio-Donahue C; Wu X; Sukumar S; Hicks J; De Marzo A; Argani P
    Breast Cancer Res; 2008; 10(5):R91. PubMed ID: 18954444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia.
    Lu YJ; Osin P; Lakhani SR; Di Palma S; Gusterson BA; Shipley JM
    Cancer Res; 1998 Oct; 58(20):4721-7. PubMed ID: 9788628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
    Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
    Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene.
    Rahman N; Stone JG; Coleman G; Gusterson B; Seal S; Marossy A; Lakhani SR; Ward A; Nash A; McKinna A; A'Hern R; Stratton MR; Houlston RS
    Br J Cancer; 2000 Feb; 82(3):568-70. PubMed ID: 10682667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lobular neoplasia.
    King TA; Reis-Filho JS
    Surg Oncol Clin N Am; 2014 Jul; 23(3):487-503. PubMed ID: 24882347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma.
    Seniski GG; Camargo AA; Ierardi DF; Ramos EA; Grochoski M; Ribeiro ES; Cavalli IJ; Pedrosa FO; de Souza EM; Zanata SM; Costa FF; Klassen G
    BMC Cancer; 2009 Mar; 9():80. PubMed ID: 19267929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective protein expression and epigenetic inactivation studies of CDH1 in patients affected by low-grade glioma.
    D'Urso PI; D'Urso OF; Storelli C; Catapano G; Gianfreda CD; Montinaro A; Muscella A; Marsigliante S
    J Neurooncol; 2011 Aug; 104(1):113-8. PubMed ID: 21127944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation.
    Toyooka KO; Toyooka S; Maitra A; Feng Q; Kiviat NC; Smith A; Minna JD; Ashfaq R; Gazdar AF
    Am J Pathol; 2002 Aug; 161(2):629-34. PubMed ID: 12163387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity.
    Reis-Filho JS; Simpson PT; Jones C; Steele D; Mackay A; Iravani M; Fenwick K; Valgeirsson H; Lambros M; Ashworth A; Palacios J; Schmitt F; Lakhani SR
    J Pathol; 2005 Sep; 207(1):1-13. PubMed ID: 15957152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.